Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
87.2(c) 87.61(c) 87.38(c) 88.3(c) 87.95 Last
3 094 809 3 046 628 3 396 257 3 917 739 1 852 446 Volume
+0.03% +0.47% -0.26% +1.05% -0.40% Change
More quotes
Financials (USD)
Sales 2018 15 133 M
EBIT 2018 8 428 M
Net income 2018 4 591 M
Debt 2018 13 270 M
Yield 2018 -
Sales 2019 16 867 M
EBIT 2019 9 566 M
Net income 2019 6 174 M
Debt 2019 6 981 M
Yield 2019 -
P/E ratio 2018 14,14
P/E ratio 2019 10,55
EV / Sales2018 4,98x
EV / Sales2019 4,10x
Capitalization 62 107 M
More Financials
Company
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases.Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
09/20CELGENE : Researchers at Celgene Report New Data on Thalidomide Analogs (In Vivo..
AQ
09/20CELGENE : New Breast Cancer Study Results Reported from Celgene (Synthetic Letha..
AQ
09/20ONCOMED PHARMACEUTICALS : Says Celgene Won't Exercise Option to License Navicixi..
DJ
09/17CELGENE CORPORATION : - OTEZLA Showed Meaningful Improvements in Clinical and Qu..
AQ
09/13EVOTEC : And Celgene Enter Partnership In The Field Of Targeted Protein Degradat..
AQ
09/12CELGENE : OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Qu..
BU
09/11EVOTEC : and Celgene enter partnership in the field of targeted protein degradat..
AQ
09/08EVOTEC : Evotech And Celgene Enter Partnership In The Field Of Targeted Protein ..
AQ
09/06CELGENE : Findings from Celgene Provides New Data on Breast Cancer [Trial-level ..
AQ
09/04TODAY'S RESEARCH REPORTS ON TRENDING : Amarin and Celgene
AC
More news
Sector news : Pharmaceuticals - NEC
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/20Animal health firm Elanco surges 41 percent on debut
RE
09/20WALL STREET STOCK EXCHANGE : Aurora Cannabis plans U.S. stock listing in October
RE
09/20ELI LILLY AND : Lilly Spinoff Elanco Animal Health Surges Early in Market Debut ..
DJ
09/20PFIZER : 20vPnC Vaccine Gets FDA Breakthrough-Therapy Designation
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on CELGENE CORPORATION 
CELGENE CORPORATION - 2017
The resistance should give in
BUY
CELGENE CORPORATION - 2017
Hesitation should subside in favor of volatility
BUY
More Strategies
Latest Tweets
09/20Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of i.. 
09/20$OMED: OncoMed Pharma: Celgene (CELG) notified the co that due to strategic p.. 
09/20Want automatic email alerts for $CELG $WH $LMRK $ATGE $HOLX? Subscribe to Mar.. 
09/20Celgene backs away from OncoMed's navicixizumab  
09/20Oncomed Pharmaceuticals : Says Celgene Won't Exercise Option to License Navic.. 
More tweets
Qtime:247
News from SeekingAlpha
09/20Celgene backs away from OncoMed's navicixizumab 
09/19Almirall's tildrakizumab OK'd in Europe for plaque psoriasis 
09/18Celgene Yields The Most 
09/18For Investors Seeking Exposure To Biotech, BB Biotech AG Might Be An Interest.. 
09/18EMA accepts Bristol-Myers' marketing application for expanded use of Emplicit.. 
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 112 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-15.39%62 107
JOHNSON & JOHNSON0.53%376 820
PFIZER19.44%253 595
NOVARTIS-0.56%216 184
ROCHE HOLDING LTD.-4.65%211 637
MERCK AND COMPANY25.79%186 114